Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of

Related Experiment Video

Updated: Mar 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Giandomenico Roviello1, Chiara Pacifico2, Giorgio Chiriacò3

  • 1Medical Oncology Unit, Department of Oncology, San Donato Hospital, Via Nenni 20, 52100 Arezzo, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy.

Critical Reviews in Oncology/Hematology
|April 22, 2017
PubMed

Insights

Orteronel, a 17,20-lyase inhibitor, improved progression-free survival and PSA response in prostate cancer patients compared to placebo. While not extending overall survival, its clinical efficacy warrants further investigation in combination therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Orteronel (TAK-700) is a selective oral non-steroidal 17,20-lyase inhibitor.
  • Previous Phase III trials indicated benefits in progression-free survival and PSA response but not overall survival.

Purpose of the Study:

  • To comprehensively assess the efficacy of orteronel in prostate cancer management.
  • To evaluate pooled data from multiple randomized trials investigating orteronel.

Main Methods:

  • Meta-analysis of data from 2716 patients across 3 randomized trials.
  • Comparison of orteronel versus placebo for key efficacy endpoints.

Main Results:

  • Orteronel significantly improved progression-free survival (PFS).
  • Orteronel demonstrated enhanced time to PSA progression and higher PSA response rates.
  • Overall survival benefit was not statistically significant in the analyzed trials.

Conclusions:

  • Despite limitations of a literature-based meta-analysis, orteronel shows clinical efficacy in prostate cancer.
  • Further research is recommended for orteronel in combination with other agents for castration-resistant prostate cancer (CRPC).
  • Investigating orteronel in earlier disease stages, such as hormone-sensitive prostate cancer, is also suggested.
Keywords:
EfficacyOrteronelPSAProstate carcinomaSurvival

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

953
Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.9K

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
307
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Urinary Tract Calculi V: Nursing Management01:28

Urinary Tract Calculi V: Nursing Management

AssessmentSubjective Data: Obtain a detailed health history, including any recent or chronic urinary tract infections, periods of immobilization, previous episodes of renal calculi, and medical conditions such as gout, benign prostatic hyperplasia, or hyperparathyroidism. Review the medication history for drugs that may influence stone formation, including allopurinol, analgesics, loop diuretics, or thiazide diuretics. Document the use of long-term indwelling catheters and any past surgical...
379
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805